Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio Pharma (Nasdaq: BBIO) has entered into an asset purchase agreement with Sentynl Therapeutics for its FDA-approved drug NULIBRY™ (Fosdenopterin). This drug is critical for reducing mortality risks in patients with the ultra-rare genetic disorder MoCD Type A. Sentynl will handle the global commercialization and development of NULIBRY, with BridgeBio sharing development responsibilities. The deal includes cash payments upon regulatory milestones and potential future royalties for BridgeBio based on net sales.
BridgeBio Pharma (BBIO) reported its Q4 2021 financial results, revealing a net loss of $147.2 million, which translates to a loss per share of $1.01. The company ended the quarter with $787.5 million in cash and equivalents, an increase from $607.1 million a year prior. Key developments included securing up to $750 million in non-dilutive debt financing, dosing its first patient in a Phase 1/2 trial for congenital adrenal hyperplasia (CAH), and initiating collaborations with Amgen and Helsinn Group to advance several oncology treatments.
BridgeBio Pharma announced the initiation of the Phase 1/2 trial for BBP-631, a gene therapy for congenital adrenal hyperplasia (CAH), marking a significant milestone in treatment options for this prevalent genetic disorder affecting over 75,000 individuals in the U.S. and EU. The trial aims to assess the safety and pharmacodynamic activity of BBP-631, potentially allowing patients to produce their own cortisol and aldosterone. Initial data is expected in the latter half of 2022, as BridgeBio advances its commitment to genetic therapies.
Atomwise, a leader in AI-driven small molecule drug discovery, has appointed David Thomson, Ph.D., as Chief Scientific Officer, alongside Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D., as General Counsel. Dr. Thomson will spearhead the company's drug development strategy, focusing on enhancing their small molecule pipeline. His extensive experience includes leadership roles at Precision BioSciences and Shire. Barr brings expertise from Bridge Bio, where he managed significant capital raises. Cerio has a strong legal background from Moderna. The team aims to advance Atomwise's innovative drug discovery capabilities.
BridgeBio Pharma has announced a non-exclusive clinical collaboration with Amgen to study the combination of BBP-398, a SHP2 inhibitor, with LUMAKRAS (sotorasib), targeting advanced solid tumors with the KRAS G12C mutation. The Phase 1/2 trial will assess safety, pharmacokinetics, and preliminary efficacy. BBP-398 aims to inhibit oncogenic processes driven by KRAS mutations, which occur in approximately 17% of solid tumors. The collaboration builds on existing partnerships with other companies, signaling BridgeBio's commitment to advancing its precision oncology pipeline.
BridgeBio Pharma (BBIO) announced mixed results from the Month 12 analysis of its Phase 3 study, ATTRibute-CM, evaluating acoramidis for treating symptomatic TTR amyloid cardiomyopathy. The primary endpoint—six-minute walk distance—did not show improvement (9m acoramidis, 7m placebo). However, notable improvements were recorded in quality of life, NT-proBNP levels, and serum TTR concentrations. Acoramidis demonstrated good tolerability with fewer adverse events leading to death. The independent monitoring committee has recommended continuing the study into the Month 30 endpoint, focusing on all-cause mortality and cardiovascular hospitalizations.
On December 6, 2021, BridgeBio Pharma (Nasdaq: BBIO) granted restricted stock units totaling 12,073 shares to nine new employees under its 2019 Inducement Equity Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and was designed to incentivize employees joining the company. Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and cancers, with a pipeline of over 30 programs and a goal of delivering its first two approved therapies.
BridgeBio Pharma and Helsinn have announced a strategic collaboration to co-develop a first-in-class GPX4 inhibitor aimed at aiding approximately 500,000 cancer patients with unmet therapeutic needs. This non-exclusive framework agreement builds on their previous $2.45 billion collaboration for the FGFR inhibitor infigratinib. The partnership will leverage BridgeBio's drug discovery expertise and Helsinn's clinical development and commercialization capabilities to enhance the oncology pipeline. The GPX4 inhibitor aims to induce ferroptosis, a process beneficial for treating difficult tumors.
BridgeBio Pharma has secured a credit facility worth up to $750 million, combined with an existing cash balance, granting access to over $1.2 billion to support its genetic disease and cancer pipeline programs through 2024. This strategic financial move, alongside a recent $150 million stock repurchase, aims to strengthen its financial position ahead of critical clinical data readouts. The financing features a 9% fixed interest rate and offers flexibility for future business opportunities.
BridgeBio Pharma (Nasdaq: BBIO) reported its third quarter 2021 financial results, revealing a net loss of $155.9 million, compared to a net loss of $115.9 million in Q3 2020. Revenue decreased to $2.3 million from $8.1 million year-over-year. Operating costs rose to $151.8 million, driven by increased R&D expenses. The company holds $599.6 million in cash and equivalents, down from $607.1 million at year-end 2020. BridgeBio continues to advance its pipeline, with 30 programs and 20 clinical trials. Notably, it received FDA approvals for two drugs earlier this year.